-
My Account
My Account
BSE Live
Apr 13, 16:00Prev. Close
2153.75
Open Price
2177.50
Bid Price (Qty.)
2130.00 (3)
Offer Price (Qty.)
2154.05 (6)
NSE Live
Apr 13, 15:57Prev. Close
2152.95
Open Price
2184.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
2159.05 (3018)
| Nine Months Results of Ipca Laboratories (in Rs. Cr.) | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
| Net Sales/Income from operations | 4,098.24 | 3,362.64 | 2,799.34 | 2,436.46 | 2,405.27 | |
| Other Operating Income | -- | -- | -- | -- | 48.68 | |
| Total Income From Operations | 4,098.24 | 3,362.64 | 2,799.34 | 2,436.46 | 2,453.95 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,146.23 | 1,060.04 | 831.88 | 699.66 | 715.64 | |
| Purchase of Traded Goods | 127.75 | 153.80 | 123.83 | 125.22 | 120.86 | |
| Increase/Decrease in Stocks | 7.42 | -60.08 | -64.93 | 31.61 | 39.05 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 711.04 | 642.91 | 575.42 | 544.22 | 516.19 | |
| Depreciation | 139.15 | 133.31 | 130.27 | 131.21 | 128.22 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 808.86 | 843.93 | 814.64 | 704.00 | 695.28 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 1,157.79 | 588.73 | 388.23 | 200.54 | 238.71 | |
| Other Income | 42.33 | 51.39 | 40.01 | 28.15 | 16.99 | |
| P/L Before Int., Excpt. Items & Tax | 1,200.12 | 640.12 | 428.24 | 228.69 | 255.70 | |
| Interest | 5.83 | 12.32 | 12.24 | 17.57 | 23.20 | |
| P/L Before Exceptional Items & Tax | 1,194.29 | 627.80 | 416.00 | 211.12 | 232.50 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 1,194.29 | 627.80 | 416.00 | 211.12 | 232.50 | |
| Tax | 205.00 | 103.10 | 70.56 | 29.32 | 88.60 | |
| P/L After Tax from Ordinary Activities | 989.29 | 524.70 | 345.44 | 181.80 | 143.90 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 989.29 | 524.70 | 345.44 | 181.80 | 143.90 | |
| Equity Share Capital | 25.37 | 25.27 | 25.27 | 25.24 | 25.24 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 78.16 | 41.53 | 27.34 | 14.41 | 11.40 | |
| Diluted EPS | 78.16 | 41.51 | 27.34 | 14.41 | 11.40 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 78.16 | 41.53 | 27.34 | 14.41 | 11.40 | |
| Diluted EPS. | 78.16 | 41.51 | 27.34 | 14.41 | 11.40 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- |
05.02.2021
Ipca Labs Consolidated December 2020 Net Sales at Rs 1,409.83 crore, up 16.24% Y-o-Y
05.02.2021
Ipca Labs Standalone December 2020 Net Sales at Rs 1,315.22 crore, up 15.46% Y-o-Y
04.02.2021
Ipca Laboratories Q3 net profit rises 35% to Rs 267.56 crore
04.02.2021
Ipca Labs Consolidated December 2020 Net Sales at Rs 1,409.83 crore, up 16.24% Y-o-Y
12.04.2021
22.01.2021
Ipca Labs Q3 PAT seen up 4.9% YoY to Rs. 207.2 cr: Yash Securities
14.10.2019
12.07.2019
IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher
